Drug intelligence / Profile preview

Ovosicare

Development stage: Unknown
Lead developer: Procare Health
Modality: Small Molecules
Administration: Oral

Overview

Ovosicare is a nutraceutical food supplement developed by Procare Health to support female fertility and improve conception chances, particularly in women with polycystic ovary syndrome (PCOS) or ovulatory dysfunction. Its formulation features Caronositol®, a proprietary 3.6:1 ratio of D-chiro-inositol and Myo-inositol, which has been clinically shown to improve oocyte quality and pregnancy rates. Additional components include Pomanox® (pomegranate extract) for antioxidant support, Quatrefolic® (active folic acid), melatonin, and a blend of essential vitamins and minerals (Vitamins D, E, B-complex, zinc, selenium, and iodine) to prepare the body for pregnancy and support embryonic development.

Brand names: OvosicareOvosicare Fertility
Other names: Ovosicare®

Targets

INSR (Insulin receptor)MTNR1A (MT1)

Beyond the preview

Go deeper on Ovosicare.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ovosicare.

Explore the full profile